(Sharecast News) - Drugmaker GSK notched two major regulatory milestones on Monday, with Japan granting the first global approval for its hepatitis B therapy Hibsago and US regulators accepting a priority review for Jemperli in previously untreated locally advanced rectal cancer.
GSK said Japan's Ministry of Health, Labour and Welfare had...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE